PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer - Archive ouverte HAL Access content directly
Journal Articles European Journal of Cancer Year : 2017

PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer

(1) , (2) , (3) , (4) , (5) , (6) , (7) , (6) , (7) , (7) , (7) , (8) , (9) , (6) , (2) , (7) , (6)
1
2
3
4
5
6
7
8
9
Anthony Gonçalves
Not file

Dates and versions

hal-03623711 , version 1 (29-03-2022)

Identifiers

Cite

Mathilde Guerin, Keyvan Rezai, Nicolas Isambert, Mario Campone, Aurélie Autret, et al.. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. European Journal of Cancer, 2017, 86, pp.28-36. ⟨10.1016/j.ejca.2017.08.025⟩. ⟨hal-03623711⟩
12 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More